| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GRIN2A |
| Uniprot No | Q12879 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 501-550aa |
| 氨基酸序列 | VYQRAVMAVGSLTINEERSEVVDFSVPFVETGISVMVSRSNGTVSPSAFLIGKAIWLLWGLVFNNSVPVQNPKGTTSKIMMHQYMTKFNQKGVEDALVSLKTGKLDAFIYDAAVLNYKAGRDEGCKLVTI |
| 预测分子量 | 18.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于GRIN2A重组蛋白研究的参考文献概览(虚拟示例，实际文献需通过数据库验证)：
1. **文献名称**: "Expression and purification of recombinant GRIN2A subunit in HEK293 cells"
**作者**: Yao, X. et al.
**摘要**: 该研究描述了在HEK293细胞中高效表达并纯化GRIN2A重组蛋白的方法，通过质谱验证其结构完整性，并证实其与GRIN1亚基共表达时形成功能性NMDA受体离子通道。
2. **文献名称**: "Functional analysis of GRIN2A mutations in epilepsy using recombinant protein models"
**作者**: Streicher, J.M. et al.
**摘要**: 研究利用重组GRIN2A蛋白系统，结合电生理学检测，揭示了与癫痫相关的多个错义突变(如p.Arg518His)对NMDA受体门控动力学和镁离子阻滞敏感性的影响。
3. **文献名称**: "Structural insights into GRIN2A ligand-binding domain interactions with allosteric modulators"
**作者**: Soto, C. et al.
**摘要**: 通过重组GRIN2A配体结合域(LBD)的晶体结构解析，阐明了正构激动剂(谷氨酸)和变构调节剂(如CIQ)的结合位点差异，为靶向药物开发提供依据。
4. **文献名称**: "GRIN2A missense variants alter synaptic receptor trafficking in recombinant neuronal models"
**作者**: Swanger, S.A. et al.
**摘要**: 利用重组GRIN2A与神经元特异性支架蛋白共表达系统，证明疾病相关突变(如p.Leu812Pro)导致受体在突触膜表面定位减少，进而影响突触可塑性。
---
*注：以上文献信息为模拟生成，实际研究需通过PubMed/Google Scholar等平台检索确认。建议使用关键词"GRIN2A recombinant protein"或"GRIN2A NMDA receptor expression"筛选近5-10年高被引论文。*
The GRIN2A gene encodes the GluN2A subunit, a critical component of N-methyl-D-aspartate (NMDA) receptors, which are ionotropic glutamate receptors central to synaptic transmission, plasticity, and learning in the central nervous system. As a member of the NMDA receptor family, GluN2A-containing receptors exhibit distinct biophysical and pharmacological properties, including high calcium permeability, voltage-dependent magnesium block, and glycine co-agonist requirements. Recombinant GRIN2A proteins are engineered to study the structure-function relationships, ligand interactions, and regulatory mechanisms of these receptors in vitro.
Produced via heterologous expression systems (e.g., mammalian or insect cells), recombinant GRIN2A proteins enable precise investigations into receptor assembly, post-translational modifications, and subunit-specific contributions to synaptic signaling. These proteins are pivotal in modeling neurological disorders linked to GRIN2A mutations, such as epilepsy, intellectual disability, and speech disorders. Pathogenic variants in GRIN2A often alter receptor kinetics, leading to excitatory-inhibitory imbalances, making recombinant variants valuable for drug screening and mechanistic studies.
Additionally, GRIN2A recombinant proteins aid in developing targeted therapeutics, including allosteric modulators or gene-editing approaches. Their use extends to structural biology (e.g., cryo-EM studies) to resolve receptor conformations and interaction interfaces. Research leveraging these proteins has advanced understanding of NMDA receptor diversity, synaptic adaptation, and their roles in neurodevelopmental and neurodegenerative diseases. Overall, GRIN2A recombinant proteins serve as indispensable tools for both basic neuroscience and translational applications.
×
